Quantel Medical has reported in a recent conference the launch of LacryDiag, a complete diagnostic device for dry eye. LacryDiag is an ocular surface analyzer that complies with the dry eye diagnosis recommendations established in the DEWS II report.
The instrument offers a fast and complete analysis of the three tear film layers with 4 non-contact exams:
- Interferometry: diagnosis of the lipid layer
- N.I.B.U.T.: diagnosis of the mucin layer
- Tear meniscus: diagnosis of the aqueous layer
- Meibography: diagnosis of the meibomian glands.
LacryDiag is CE marked and is approved by the U.S. Food and Drug Administration (FDA). Quantel Medical has made the launch announcement during the last World Ophthalmology Congress held in Barcelona, Spain, June 17-19.
“Dry eye is a real public health problem but the symptoms are often misunderstood. As a multifactorial pathology that results from damage to the tear film due, this pathology is often underdiagnosed and underestimated, explains Jean-Marc Gendre, CEO Quantel Medical. With LacryDiag, the ophthalmologists are now able to diagnosis in a few minutes the three tear film layers to select a personalized treatment for the patient.”
See the press release from Quantel Medical.